Navigation Links
Infinity and MedImmune to Present Preclinical Data From Study of,Oral Formulation of IPI-504 At AACR

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

CAMBRIDGE, Mass. and GAITHERSBURG, Md., April 10, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that data from a preclinical study with an oral formulation of IPI-504 in non-small cell lung cancer (NSCLC) will be presented at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) in Los Angeles, Calif., April 14-18, 2007. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials involving patients with gastrointestinal stromal tumors (GIST) and NSCLC.

An oral presentation of the data, titled "IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC" (Abstract No. 5726) is scheduled to begin at 9:10 a.m. PDT on Wednesday, April 18, 2007 in Room 501 A-C in the Los Angeles Convention Center.

About IPI-504

IPI-504 is a small molecule drug candidate being developed jointly by Infinity and MedImmune. IPI-504 has been well-tolerated in its ongoing Phase I studies and has shown promising biological activity in a Phase I clinical trial in patients with relapsed, refractory Gleevec(r)-resistant GIST. IPI-504 is also being evaluated in a Phase I/II clinical trial in patients with advanced NSCLC. In preclinical studies, IPI-504 has been shown to inhibit Hsp90 potently and selectively, thereby killing cancer cells. IPI-504 has also demonstrated, in preclinical studies, broad potential to treat certain cancers as both a single agent as well as in combination with existing anti-cancer drugs. The water-based formulation of IPI-504 is delivered as an intravenous infusion; an oral formulation of IPI-504 is currently
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/25/2009)...dsandJOHANNESBURG,November25/PRNewswire/--,iThemba...nouncedtoday,thattheyhavesignedacollaborativeagree... Pyxis,sworldclasscomputationalchemistryandleaddis...ivisiontoprovidemedicinaland,syntheticchemistrysup...lclientnetwork.iThembaPharmaceuticalsandPyxisDisco...
(Date:11/25/2009)....,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,announce...ROTECT-1(theProspectiveRandomizedOralTherapyEvalua...-B)inpatientswithmoderate-to-severeCrohn,sdiseased...tolerabilityprofile.Thestudydemonstratedevidenceof...efinedasa70-pointdecreaseintheCrohn,sDiseaseActivi...
(Date:11/24/2009)...PRNewswire/-- ,, WHAT:RomHoubens,aBelgianmantho...ent,wasactuallyfullyconsciousandawakeduringthattim...ynaVoxEyeMaxwasfeaturedinthesegmenttoillustratehow...lockcommunication. ,, WHEN:GoodMorningAmerica--...oxtech.com ,, WHO:RomHoubenswasanengineerin...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Emdeon Acquires eRx Network LLC 50665 1Emdeon Acquires eRx Network LLC 50665 2Emdeon Acquires eRx Network LLC 50665 3New Drug Could Work Against Leukemia 50663 1Sexist jokes favor the mental mechanisms that justify violence against women 50661 1Sexist jokes favor the mental mechanisms that justify violence against women 50661 2
...cals, a division of Wyeth (NYSE: WYE ), announced...(FDA) has issued an approvable letter for,the firs... the treatment of,adult patients with community-ac..., the FDA requested that Wyeth provide,additional ...ACIL for the,treatment of patients with CAP with i...
...val Benefit in Complete and Partial Respo...HEIGHTS, N.J., May 29 Genta,Incorporated (OTC Bul...erm,followup from a Phase 3 trial of the Company,s...dium) Injection, in patients with chronic,lymphocy...data show that,patients who achieved either a comp...
Other Medicine Technology:Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 2Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 3Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 4Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 5Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:11/25/2009)...nimally-invasive procedures that provide patients ...k of sinusitis, or sinus infection, are being deve...oring Institute. Techniques such as balloon sinup...having to remove any bone or tissue like tradition...throughs in treating sinus symptoms were featured ...
(Date:11/25/2009)...wire/--Therearemanywaysyoucanimprove,yourhealth,an...waysseemstobeconflictingadviceconcerningwhatisgood...o,therealbuzz.comteamhascompiledalistof25health-bo...tible!Doingacombinationof,oursuggestedactivitieswi...eing-sotrythemout. , 1.Reduceyourfatintake.Th...
(Date:11/24/2009)...ercent of radiation oncologists use advanced imagi... (FDG-PET), magnetic resonance imaging (MRI), and ...t delineation (to locate the tumor and other areas...le in the December issue of the Journal of the Am...rg ). , In defining the target, the radiation on...
(Date:11/24/2009)...of Miami School of Medicine compared the outcomes ...nts for nonalcoholic steatohepatitis (NASH) versus...stically significant differences in post-transplan... Study findings are presented in the December issu...by Wiley-Blackwell on behalf of the American Assoc...
(Date:11/24/2009)...ton University School of Medicine (BUSM) and the B... have identified a number of proteins whose activa... normal cells with almost 97 percent accuracy. In ...computational strategy to analyze this data and sp...ular circuits) that are active in cancer and "dorm...
Breaking Medicine News(10 mins):Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:realbuzz.com - Top 25 Ways to Improve Your Health & get a Better Sex Life! 2Health News:New data emerges on liver transplant survival rates 2Health News:New data emerges on liver transplant survival rates 3Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2
...covered that suffering from infection increases th...hich is a dangerous condition in which blood clots... That infection can cause an increase in the risk ... that infection can also cause DVT. Research...
...h HIV/AIDS have opposed a patent application filed...ir, a fixed dose combination AIDS drug on the grou... // Represented by the Lawyers' Collective ...tion to a patent application filed at the Kolkata ...
...ical Center and John Hopkins University School of ...aling pathway that plays a vital role in the embry...o injury lead to the development of liver cancer. ...rgeted treatment of liver cancer, which happens to...
... propagate a new method of sex education for young...vice president with the China Family Planning Asso... arrived earlier in recent years, but sex educatio...ar. Education on sex and reproductive health ...
... among city kids in Britain, increasing their susc...archers, only 37% of the urban kids really walk to...suburban areas. Nearly 47% of the kids spend almos...he above 40 age group. In Britain, more than ...
...ggests, that a pain killing medication helps by ha... common form of breast cancer. The name of the pai...iments on breast cancer cells, scientists found th...e most common breast cancer in postmenopausal wome...
Other Medicine News:Health News:HIV Patients Opposes Patenting Of AIDS Drug 2Health News:Unchecked Cellular Repair Pathway Causes Liver Cancer 2Health News:Pain-killer Drug Can Help Fight Breast Cancer 2
O.R. Special Procedure Apron
Special Procedure Apron
Easy Wrap Apron
Disposable Monopolar NeedleElectrodes With Detachable Lead Wire
Medicine Products: